News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Centers for Medicare & Medicaid Services publish final rate of $192 for Epigenomics’ colorectal cancer screening blood test Epi proColon®

PDF Berlin (Germany) and San Diego, CA (U.S.A.), October 22, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that the Centers for Medicare & Medicaid Services (CMS) published a final rate of $192 for Epi proColon, the first and only FDA-approved blood test for colorectal cancer screening. This announcement confirms the […]

Read more

Epigenomics AG: Capital increase through rights issue with subscription rights of existing shareholders

PDF NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN AND AUSTRALIA. Epigenomics AG: Capital increase through rights issue with subscription rights of existing shareholders -Issuance of up to 12,007,180 new shares -Shareholders granted subscription rights at a ratio of 2:1 -Subscription price will be […]

Read more

Epigenomics AG: U.S. Congress supports CMS coverage of colorectal cancer screening blood tests

PDF Berlin (Germany) and San Diego, CA (U.S.A.), October 2, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that the U.S. Congress urges the Centers of Medicare & Medicaid Services (CMS) to consider coverage of colorectal cancer screening blood tests as part of the approved 2019 Health and Human Services (HHS) […]

Read more

Epigenomics AG Announces 2018 Second Quarter and Six Month Financial Results

PDF Berlin (Germany) and San Diego, CA (U.S.A.), August 8, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced its financial results for the second quarter and the first six months 2018 ending June 30. “While we continue to pursue our objective of Medicare coverage for Epi proColon® in the U.S., we […]

Read more

Liquid Biopsy Test for Liver Cancer Detection to obtain CE Mark

PDF -Epigenomics plans to CE Mark mSEPT9 blood test for liver cancer by year-end 2018, enabling commercialization in Europe -Prospective U.S. trial for FDA submission to be initiated in 2019 -Investigating optimal path for CFDA approval in China Berlin (Germany) and San Diego, CA (U.S.A.), July 2, 2018 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY) […]

Read more

Centers for Medicare & Medicaid Services publish preliminary rate for Epigenomics’ colorectal cancer screening test Epi proColon®

PDF Medicare Administrative Contractors determine rate of $192 per test Berlin (Germany) and Germantown, MD (U.S.A.), June 11, 2018 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), announced that the Centers for Medicare & Medicaid Services (CMS) published a preliminary rate of $192 per Epi proColon test. Epi proColon is the first and only FDA-approved […]

Read more